Replies to post #200 on Trillium Therapeutics Inc (TRIL)

[NY1972]

ASCO URL

http://abstracts.asco.org/176/AbstView_176_162472.html

[NY1972]

No calreticulin effect? 75 mil from billionaires for 2 SD, nice to live in wealthy neighborhood.

we have identified LDL receptor-related protein (LRP-1), which by recognizing calreticulin on the surface of normal erythrocytes can mediate phagocytosis of untreated CD47-deficient erythrocytes [141, 142]. By showing that macrophages in the splenic red pulp can recognize normal circulating erythrocytes, but that these macrophages do not phagocytose erythrocytes as long as they display CD47 on their surface, these findings were the first to prove that macrophages are perfectly capable of recognizing “normal” host cells and rely on “self” recognition for proper function.

[NY1972]

47 CEO:

25 patients have been treated

not seeing the kinds of side effects that have been seen with checkpoint inhibitors in terms of skin sensitivity or GI problems.

plasma concentration levels which are the same as seen in preclinical work, which MacQuitty says were very strong, and is therefore showing an early translation into the clinic.

http://www.fiercebiotech.com/special-report/forty-seven